eCORE
- Cancer
Team
Group Leader
Juan Angel Recio Conde, Vicente García-Patos Briones
Researchers
Kimberley MacGrail
PhD Students
Paula Granado Martínez, Roberto Orsenigo, Carlos González Cruz, Yuxin Ding, Berta Ferrer
Selected Publications
Clavero-Rovira L, Gómez-Tomás Á, Bassas-Freixas P, Bodet D, Ferrer B, Hernández-Losa J, Muñoz-Couselo E, Pérez-Benavente A, García-Patos V, Ferrándiz-Pulido C
Mucosal Melanoma Clinical Management and Prognostic Implications: A Retrospective Cohort Study.
Cancers (Basel)
DOI: 10.3390/cancers16010227.
IF: 4.55
McGrail K, González-Sánchez E, Granado-Martínez P, Orsenigo R, Ding Y, Ferrer B, Hernández-Losa J, Ortega I, Martín-Caballero J, Muñoz-Couselo E, García-Patos V, Recio JA
Loss of Lkb1 cooperates with BrafV600E and ultraviolet radiation, increasing melanoma multiplicity and neural-like dedifferentiation.
Mol Oncol. 2025 Feb;19(2):329-343.Epub 2024 Aug 8.
DOI: 10.1002/1878-0261.13715
IF: 6.6
González-Cruz C, Muñoz-Couselo E, Ortiz-Velez C, Ferrer B, García-Patos V, Ferrándiz-Pulido C.
Complete response of metastatic cutaneous squamous cell carcinoma and multiple locally advanced basal cell carcinomas with concomitant pembrolizumab and sonidegib therapy.
JAAD . 2024 Mar 1;46:67-69.
DOI: 10.1016/j.jdcr.2024.02.011
IF: 11.5
Combined immunotherapy in melanoma patients with brain metastases: A multicenter international study. Mandalà M, Lorigan P, Sergi MC, Benannoune N, Serra P, Vitale MG, Giannarelli D, Arance AM, Couselo EM, Neyns B, Tucci M, Guida M, Spagnolo F, Rossi E, Occelli M, Queirolo P, Quaglino P, Depenni R, Merelli B, Placzke J, Di Giacomo AM, Del Vecchio M, Indini A, da Silva IP, Menzies AM, Long GV, Robert C, Rutkowski P, Ascierto PA.Combined immunotherapy in melanoma patients with brain metastases: A multicenter international study.
Combined immunotherapy in melanoma patients with brain metastases: A multicenter international study.
Eur J Cancer. 2024 Mar;199:113542
DOI: 10.1016/j.ejca.2024.113542
IF: 7.6
Selected Projects
p38αtumor-dependent immune evasive mechanisms in melanoma
Principal Investigator: Juan A. Recio
Agency: Instituto de Salud Carlos III
Funding: 321,250 €
Period: 01/01/2024 - 01/01/2027
Development of TET2 activating drugs for the treatment of melanoma
Principal Investigator: Juan A. Recio, Isabel Puig; Hector García Palmer
Agency: Ministerio de Economía y competitividad
Funding: 723,392.47 €
Period: 15/11/2023 - 15/11/2026
Molecular mechanisms in melanomaJuan A. Recio Conde
Principal Investigator: Juan Angel Recio Conde
Agency: Generalitat de Catalunya
Funding: 60,000 €
Period: 31/01/2021 - 31/01/2025